February 2021 Content Release Copied

03/04/20212021 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile: Problems

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

Name Change Options Added Options Removed
DCISionRT scoring Added inference group for Breast cancer, female
Fallopian Tube Cancer HRD status Renamed to Fallopian Tube Cancer HR status
  • Deficient
  • Proficient
  • Unknown
  • Positive
  • Negative
Ovarian and Primary Peritoneal Cancer HRD status Renamed to Ovarian and Primary Peritoneal Cancer HR status
  • Deficient
  • Proficient
  • Unknown
  • Positive
  • Negative

Document Types Additions and Updates

Biomarker Requisition

Admix

Admix Fluid options now include:

  • D5w (Non-Dehp) (Dextrose 5 % In Water)
  • Normal saline (Non-Dehp) (0.9 % Sodium Chloride)

Lab Analyte and Panel Additions and Updates

  • +8 – nuclei analyzed
  • +8 – result
  • +8/20q-/-20 (Chromosome 20) – 1R1G total counts
  • +8/20q-/-20 (Chromosome 20) – 1R2G total counts
  • +8/20q-/-20 (Chromosome 20) – 2R1G total counts
  • +8/20q-/-20 (Chromosome 20) – 2R2G total counts
  • +8/20q-/-20 (Chromosome 20) nuclei analyzed
  • +8/20q-/-20 (Chromosome 20) result
  • +8/20q-/-20 (Chromosome 8) – 2A total counts
  • +8/20q-/-20 (Chromosome 8) – 3A total counts
  • +8/20q-/-20 (Chromosome 8) nuclei analyzed
  • +8/20q-/-20 (Chromosome 8) result
  • 5q-/-5/+5 tricolor – 1R1G1A total counts
  • 5q-/-5/+5 tricolor – 1R1G2A total counts
  • 5q-/-5/+5 tricolor – 1R2G2A total counts
  • 5q-/-5/+5 tricolor – 2R1G2A total counts
  • 5q-/-5/+5 tricolor – 2R2G2A total counts
  • 5q-/-5/+5 tricolor – nuclei analyzed
  • 5q-/-5/+5 tricolor – result
  • 6q- FISH – 6q- FISH
  • 7q-/-7 tri – 1R1G1A total counts
  • 7q-/-7 tri – 1R1G2A total counts
  • 7q-/-7 tri – 1R2G2A total counts
  • 7q-/-7 tri – 2R1G2A total counts
  • 7q-/-7 tri – 2R2G2A total counts
  • 7q-/-7 tri – nuclei analyzed
  • 7q-/-7 tri – result
  • AKT1 mutation analysis – AKT1 mutation analysis
  • AKT1 mutation analysis – mutation(s)
  • ALK for Lymphoma comments
  • ALK for Lymphoma nuclei analyzed
  • ALK for Lymphoma panel
  • ALK for Lymphoma result
  • ALK mutation analysis – ALK mutation analysis
  • ALK mutation analysis – mutation(s)
  • ALK mutation analysis – mutations(s)
  • ALL adult FISH comments
  • ALL adult FISH panel
  • ALL pediatric FISH comments
  • ALL pediatric FISH panel
  • AML favorable-risk comments
  • AML favorable-risk panel
  • AML favorable-risk PDF
  • AML non-favorable risk FISH comments
  • AML non-favorable risk FISH panel
  • AML standard FISH comments
  • AML standard FISH panel
  • APC mutation analysis – APC mutation analysis
  • APC mutation analysis – mutation(s)
  • API2/MALT1 t(11;18) comments
  • API2/MALT1 t(11;18) nuclei analyzed
  • API2/MALT1 t(11;18) panel
  • API2/MALT1 t(11;18) result
  • ARAF mutation analysis
  • ARAF mutation analysis – mutation(s) detected
  • ARID1A mutation analysis – ARID1A mutation analysis
  • ARID1A mutation analysis – mutation(s)
  • ATM mutation analysis – ATM mutation analysis
  • ATM mutation analysis – mutation(s)
  • ATR mutation analysis – ATR mutation analysis
  • BAP1 mutation analysis – BAP1 mutation analysis
  • BAP1 mutation analysis – mutation(s)
  • BARD1 mutation analysis – BARD1 mutation analysis
  • BARD1 mutation analysis – mutation(s) detected
  • BCL2 (18q21) – 1R1G1F total counts
  • BCL2 (18q21) – 2F total counts
  • BCL2 (18q21) – nuclei analyzed
  • BCL2 (18q21) result
  • BCL2 mutation analysis – BCL2 mutation analysis
  • BCL2 mutation analysis – mutation
  • BCL6 (3q27) – 1R1G1F total counts
  • BCL6 (3q27) – 2F total counts
  • BCL6 (3q27) nuclei analyzed
  • BCL6 (3q27) result
  • BCR/ABL1/ASS1 t(9;22) nuclei analyzed
  • BCR/ABL1/ASS1 t(9;22) result
  • BIRC3 mutation analysis – mutation(s) detected
  • BLM mutation analysis – BLM mutation analysis
  • BLM mutation analysis – mutation(s) detected
  • BRAF – Nuclei analyzed
  • BRAF – Result
  • BRAF mutation analysis – BRAF mutation
  • BRAF mutation analysis – mutation(s)
  • BRCA1 mutation analysis – BRCA1 mutation analysis
  • BRCA1 mutation analysis – mutation(s)
  • BRCA2 mutation analysis – BRCA2 mutation analysis
  • BRCA2 mutation analysis – mutation(s)
  • BRIP1 mutation analysis – BRIP1 mutation analysis
  • BRIP1 mutation analysis – mutation(s) detected
  • BTK mutation analysis – BTK mutation analysis
  • BTK mutation analysis – mutation(s)
  • CARD11 mutation analysis – CARD11 mutation analysis
  • CARD11 mutation analysis – mutation(s) detected
  • CBFB (16q22) – 1F total counts
  • CBFB (16q22) – 1R1G1F total counts
  • CBFB (16q22) – 2F total counts
  • CBFB (16q22) nuclei analyzed
  • CBFB (16q22) panel
  • CBFB (16q22) result
  • CCND1/IgH t(11;14) – result
  • CCND1/IgH t(11;14) comments
  • CCND1/IgH t(11;14) FISH – CCND1/IgH t(11;14) FISH
  • CCND1/IgH t(11;14) nuclei analyzed
  • CCND1/IgH t(11;14) panel
  • CCND1/IgH t(11;14) result
  • CD79B mutation analysis – mutation(s)
  • CDH1 mutation analysis – CDH1 mutation analysis
  • CDH1 mutation analysis – mutation(s)
  • CDK12 mutation analysis – CDK12 mutation analysis
  • CDK12 mutation analysis – mutation(s)
  • CDKN2A mutation analysis – CDKN2A mutation analysis
  • CDKN2A mutation analysis – mutation(s)
  • Centromere 4\T\17 (Chromosome 17) – nuclei analyzed
  • Centromere 4\T\17 (Chromosome 17) – result
  • Centromere 4\T\17 (Chromosome 4) – nuclei analyzed
  • Centromere 4\T\17 (Chromosome 4) – result
  • Centromere 6\T\10 (Chromosome 10) – nuclei analyzed
  • Centromere 6\T\10 (Chromosome 10) – result
  • Centromere 6\T\10 (Chromosome 6) – nuclei analyzed
  • Centromere 6\T\10 (Chromosome 6) – result
  • CHEK1 mutation analysis – CHEK1 mutation analysis
  • CHEK1 mutation analysis – mutation(s) detected
  • CHEK2 mutation analysis – CHEK2 mutation analysis
  • CHEK2 mutation analysis – mutation(s) detected
  • Chromosome 19pq nuclei analyzed
  • Chromosome 19pq result
  • Chromosome 1pq nuclei analyzed
  • Chromosome 1pq result
  • Chromosomes 11 \T\ 17 FISH – Chromosome 11 FISH
  • Chromosomes 11 \T\ 17 FISH – Chromosome 17 FISH
  • Chromosomes 12 \T\ 13 FISH – Chromosome 12 FISH
  • Chromosomes 12 \T\ 13 FISH – Chromosome 13 FISH
  • COMPASS blood evaluation comments
  • COMPASS blood evaluation flow cytometry
  • COMPASS blood evaluation morphology
  • COMPASS blood evaluation panel
  • COVID-19 PUI Ag panel
  • COVID-19 PUI Ag, qual
  • CSF1R mutation analysis – mutation(s)
  • CTNNB1 mutation analysis – CTNNB1 mutation analysis
  • CTNNB1 mutation analysis – mutation(s)
  • CXCR4 mutation analysis – mutation(s)
  • DEK/NUP214 (CAN) t(6;9) – nuclei analyzed
  • DEK/NUP214 (CAN) t(6;9) – result
  • Donath Landsteiner Ab
  • Donath Landsteiner Ab panel
  • EGFR mutation analysis by Sanger – EGFR Exon 18
  • EGFR mutation analysis by Sanger – EGFR Exon 19
  • EGFR mutation analysis by Sanger – EGFR Exon 20 Other mutations
  • EGFR mutation analysis by Sanger – EGFR Exon 20 T790M
  • EGFR mutation analysis by Sanger – EGFR Exon 21
  • EGFR mutation analysis by Sanger – Overall result
  • ER allred score
  • ER comments
  • ER intensity
  • ER internal control
  • ER panel
  • ER result
  • ER tumor stained
  • ER tumor type
  • ERBB2 mutation analysis – ERBB2 mutation analysis
  • ERBB2 mutation analysis – mutation(s)
  • ERBB4 mutation analysis – ERBB4 mutation analysis
  • ERBB4 mutation analysis – mutation(s)
  • ESR1 mutation analysis – ESR1 mutation analysis
  • ESR1 mutation analysis – mutation(s)
  • ETV6 (12p13) – nuclei analyzed
  • ETV6 (12p13) – result
  • ETV6/RUNX1 (TEL/AML1) t(12;21) – nuclei analyzed
  • ETV6/RUNX1 (TEL/AML1) t(12;21) – result
  • FANCA mutation analysis – FANCA mutation analysis
  • FANCA mutation analysis – mutation(s) detected
  • FANCC mutation analysis – FANCC mutation analysis
  • FANCC mutation analysis – mutation(s) detected
  • FANCD2 mutation analysis – FANCD2 mutation analysis
  • FANCD2 mutation analysis – mutation(s) detected
  • FANCE mutation analysis – FANCE mutation analysis
  • FANCE mutation analysis – mutation(s) detected
  • FANCF mutation analysis – FANCF mutation analysis
  • FANCF mutation analysis – mutation(s) detected
  • FANCG mutation analysis – FANCG mutation analysis
  • FANCG mutation analysis – mutation(s) detected
  • FANCL mutation analysis – FANCL mutation analysis
  • FANCL mutation analysis – mutation(s) detected
  • FBXW7 mutation analysis – FBXW7 mutation analysis
  • FBXW7 mutation analysis – mutation(s)
  • FGFR1 mutation analysis – FGFR1 mutation analysis
  • FGFR1 mutation analysis – mutation(s)
  • FGFR2 (10q26.13) – FGFR2 (10q26.13)
  • FGFR2 (10q26.13) nuclei analyzed
  • FGFR2 (10q26.13) result
  • FGFR2 mutation analysis – FGFR2 mutation analysis
  • FGFR2 mutation analysis – mutation(s)
  • FGFR3 mutation analysis – FGFR3 mutation analysis
  • FGFR3 mutation analysis – mutation(s)
  • GATA3 mutation analysis – GATA3 mutation analysis
  • GATA3 mutation analysis – mutation(s) detected
  • GNA11 mutation analysis – mutation(s)
  • GNAQ mutation analysis – mutation(s)
  • GNAS mutation analysis – mutation(s)
  • HER2 breast comments
  • HER2 breast panel
  • HER2 breast percentage of cells with uniform intense complete membrane staining
  • HER2 breast result
  • HER2 breast score
  • HER2 Non-Breast comments
  • HER2 Non-Breast nuclei analyzed
  • HER2 Non-Breast panel
  • HER2 Non-Breast result
  • High-grade/Large B-Cell lymphoma FISH comments
  • High-grade/Large B-Cell lymphoma FISH panel
  • High-grade/Large B-Cell lymphoma FISH PDF
  • HNF1A mutation analysis – mutation(s)
  • HPV DNA tissue test
  • HRAS mutation analysis – HRAS mutation
  • HRAS mutation analysis – mutation(s)
  • IDH1/IDH2 mutation analysis – IDH1 mutation
  • IDH1/IDH2 mutation analysis – IDH1/IDH2 mutation
  • IDH1/IDH2 mutation analysis – IDH2 mutation
  • IgH (14q32) comments
  • IgH (14q32) nuclei analyzed
  • IgH (14q32) panel
  • IgH (14q32) result
  • IgH/BCL2 t(14;18) nuclei analyzed
  • IgH/BCL2 t(14;18) result
  • IgVH mutation for NTP – expressed VH family(s)
  • IgVH mutation for NTP – IGVH mutation
  • IgVH mutation for NTP – mutation rate
  • KDR mutation analysis – mutation(s)
  • KIT (c-KIT) mutation analysis – c-KIT Exon 11
  • KIT (c-KIT) mutation analysis – c-KIT Exon 17
  • KIT (c-KIT) mutation analysis – c-KIT Exon 8
  • KIT (c-KIT) mutation analysis – c-KIT Exon 9
  • KIT (c-KIT) mutation analysis – KIT (c-Kit) mutation
  • KMT2A (MLL) (11q23)* – >2F total counts
  • KMT2A (MLL) (11q23)* – 1F total counts
  • KMT2A (MLL) (11q23)* – 1R1F total counts
  • KMT2A (MLL) (11q23)* – 1R1G1F total counts
  • KMT2A (MLL) (11q23)* – 2F total counts
  • KMT2A (MLL) (11q23)* – nuclei analyzed
  • KMT2A (MLL) (11q23)* – result
  • KRAS mutation analysis – KRAS mutation
  • KRAS mutation analysis – mutation(s)
  • LDH panel, peritoneal fluid
  • LDH, peritoneal fluid
  • MALT1 (18q21) nuclei analyzed
  • MALT1 (18q21) result
  • MAP2K1 mutation analysis – mutation(s) detected
  • MET (c-MET) mutation analysis – MET (c-MET) mutation
  • MET (c-MET) mutation analysis – mutation(s)
  • MET FISH – MET FISH
  • MET nuclei analyzed
  • MET result
  • MLH1 mutation analysis – mutation(s)
  • MLH1 sequencing – MLH1 sequencing
  • MLH1 sequencing – result
  • MMA urine panel
  • MMA, mmol/mol creat
  • MMA, urine source
  • MRE11A mutation analysis – MRE11A mutation analysis
  • MRE11A mutation analysis – mutation(s) detected
  • MSH2 sequencing – MSH2 sequencing
  • MSH2 sequencing – result
  • MSH6 sequencing – MSH6 sequencing
  • MSH6 sequencing – result
  • MSI by NGS – microsatellite instability
  • MTOR mutation analysis – mutation(s) detected
  • MYC (8q24) – 1R1G1F total counts
  • MYC (8q24) – 2F total counts
  • MYC (8q24) nuclei analyzed
  • MYC (8q24) result
  • MYCN amp – Nuclei analyzed
  • MYCN amp – Result
  • MYD88 mutation analysis – mutation(s) detected
  • NBN mutation analysis – mutation(s) detected
  • NBN mutation analysis – NBN mutation analysis
  • NeoTYPE precision profile for solid tumors comments
  • NeoTYPE precision profile for solid tumors PDF
  • NeoTYPE(TM) Brain tumor FISH comments
  • NeoTYPE(TM) Brain tumor FISH panel
  • NeoTYPE(TM) Brain tumor FISH PDF
  • NeoTYPE(TM) Breast tumor FISH comments
  • NeoTYPE(TM) Breast tumor FISH panel
  • NeoTYPE(TM) Breast tumor profile
  • NeoTYPE(TM) Breast tumor profile comments
  • NeoTYPE(TM) Cervical tumor FISH comments
  • NeoTYPE(TM) Cervical tumor FISH panel
  • NeoTYPE(TM) CLL prognostic comments
  • NeoTYPE(TM) CLL prognostic profile
  • NeoTYPE(TM) Endometrial tumor FISH comments
  • NeoTYPE(TM) Endometrial tumor FISH panel
  • NeoTYPE(TM) Esophageal tumor comments
  • NeoTYPE(TM) Esophageal tumor FISH comments
  • NeoTYPE(TM) Esophageal tumor FISH panel
  • NeoTYPE(TM) Esophageal tumor profile
  • NeoTYPE(TM) Gastric tumor FISH comments
  • NeoTYPE(TM) Gastric tumor FISH panel
  • NeoTYPE(TM) Head & Neck tumor profile
  • NeoTYPE(TM) Head & Neck tumor profile comments
  • NeoTYPE(TM) Liver/Biliary tumor comments
  • NeoTYPE(TM) Liver/Biliary tumor FISH comments
  • NeoTYPE(TM) Liver/Biliary tumor FISH panel
  • NeoTYPE(TM) Liver/Biliary tumor profile
  • NeoTYPE(TM) NTRK1, 2, 3 comments
  • NeoTYPE(TM) NTRK1, 2, 3 panel
  • NeoTYPE(TM) precision profile for solid tumors
  • NeoTYPE(TM) Thyroid FISH comments
  • NeoTYPE(TM) Thyroid FISH panel
  • NeoTYPE(TM) Thyroid FISH PDF
  • NF1 mutation analysis – mutation(s)
  • NF1 mutation analysis – NF1 mutation analysis
  • NFE2L2 mutation analysis – mutation(s) Detected
  • NFE2L2 mutation analysis – NFE2L2 mutation analysis
  • NHL comments
  • NHL panel
  • NOTCH1 mutation analysis – mutation(s) Detected
  • NOTCH1 mutation analysis – NOTCH1 mutation analysis
  • NRAS mutation analysis – mutation(s)
  • NRAS mutation analysis – NRAS mutation
  • NTRK1 (1q23.1) – nuclei analyzed
  • NTRK1 (1q23.1) – result
  • NTRK1, 2, 3 FISH panel
  • NTRK2 (9q21.33) – nuclei analyzed
  • NTRK2 (9q21.33) – result
  • NTRK3 (15q25.3) – nuclei analyzed
  • NTRK3 (15q25.3) – result
  • p53 (17p13.1)/ NF1 (17q11) – nuclei analyzed
  • p53 (17p13.1)/ NF1 (17q11) – result
  • PALB2 mutation analysis – mutation(s)
  • PALB2 mutation analysis – PALB2
  • Pan-TRK – Marker result
  • Pan-TRK – Pan-TRK
  • PBRM1 mutation analysis – mutation(s)
  • PBRM1 mutation analysis – PBRM1 mutation analysis
  • PBX1/TCF3 t(1;19) – nuclei analyzed
  • PBX1/TCF3 t(1;19) – result
  • PDGFRa amp – Nuclei Analyzed
  • PDGFRa amp – Result
  • PDGFRa mutation analysis – mutation(s) detected
  • PDGFRa mutation analysis – PDGFRa mutation(s)
  • PD-L1 22C3 FDA (KEYTRUDA) for ESCC (Esophageal Squamous Cell Carcinoma) – PD-L1 22C3 FDA (KEYTRUDA) for ESCC (Esophageal Squamous Cell Carcinoma)
  • PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA – PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA
  • PD-L1 22C3 FDA (KEYTRUDA) for HNSCC (Head and Neck) – PD-L1 22C3 FDA (KEYTRUDA) for HNSCC (Head and Neck)
  • PD-L1 SP142 FDA (TECENTRIQ) for TNBC (Breast) –  % Immune Cells Stained
  • PD-L1 SP142 FDA (TECENTRIQ) for TNBC (Breast) –  IC Intensity
  • PD-L1 SP142 FDA (TECENTRIQ) for TNBC (Breast) –  PD-L1 SP142 FDA (TECENTRIQ) for TNBC (Breast)
  • PD-L1 SP142 FDA (TECENTRIQ) for Urothelial Carcinoma – % Immune Cells Stained
  • PD-L1 SP142 FDA (TECENTRIQ) for Urothelial Carcinoma – intensity
  • PD-L1 SP142 FDA (TECENTRIQ) for Urothelial Carcinoma – result
  • PD-L1 SP142 FDA (TECENTRIQ) for Urothelial Carcinoma comments
  • PD-L1 SP142 FDA (TECENTRIQ) for Urothelial Carcinoma panel
  • PIK3CA LDT mutation analysis by sequencing – PIK3CA Exon 1
  • PIK3CA LDT mutation analysis by sequencing – PIK3CA Exon 20
  • PIK3CA LDT mutation analysis by sequencing – PIK3CA Exon 9
  • PIK3CA LDT mutation analysis by sequencing – PIK3CA mutation
  • PLCG2 mutation analysis – mutation
  • PML/RARA t(15;17) – 1R1G1F total counts
  • PML/RARA t(15;17) – 1R1G2F total counts
  • PML/RARA t(15;17) – 2R2G total counts
  • PML/RARA t(15;17) – 2R3G total counts
  • PML/RARA t(15;17) nuclei analyzed
  • PML/RARA t(15;17) result
  • PML/RARA t(15;17), FISH
  • PMS2 sequencing – PMS2 sequencing
  • PMS2 sequencing – result
  • PTCH1 mutation analysis – mutation(s)
  • PTEN (10q23) comments
  • PTEN (10q23) nuclei analyzed
  • PTEN (10q23) panel
  • PTEN (10q23) result
  • PTEN FISH – Note
  • PTEN FISH – PTEN FISH
  • PTEN mutation analysis – mutation(s) detected
  • PTEN mutation analysis – PTEN mutation analysis
  • PTPN11 mutation analysis – mutation(s) detected
  • RAD50 mutation analysis – mutation(s) detected
  • RAD50 mutation analysis – RAD50 mutation analysis
  • RAD51 mutation analysis – mutation(s) detected
  • RAD51 mutation analysis – RAD51 mutation analysis
  • RAD51B mutation analysis – mutation(s)
  • RAD51B mutation analysis – RAD51B mutation analysis
  • RAD51C mutation analysis – mutation(s)
  • RAD51C mutation analysis – RAD51C mutation analysis
  • RAD51D mutation analysis – mutation(s) detected
  • RAD51D mutation analysis – RAD51D mutation analysis
  • RAD54L mutation analysis – mutation(s) detected
  • RAD54L mutation analysis – RAD54L mutation analysis
  • RB1 mutation analysis – mutation(s)
  • RB1 mutation analysis – RB1 mutation analysis
  • RET comments
  • RET FISH – RET FISH
  • RET mutation analysis – mutation(s)
  • RET nuclei analyzed
  • RET panel
  • RET result
  • ROS1 comments
  • ROS1 nuclei analyzed
  • ROS1 panel
  • ROS1 result
  • RPN1/MECOM (3q) – nuclei analyzed
  • RPN1/MECOM (3q) – result
  • RUNX1/RUNX1T1 (ETO/AML1) t(8;21) – 1R1G1F total counts
  • RUNX1/RUNX1T1 (ETO/AML1) t(8;21) – 1R1G2F total counts
  • RUNX1/RUNX1T1 (ETO/AML1) t(8;21) – 2R2G total counts
  • RUNX1/RUNX1T1 (ETO/AML1) t(8;21) – 2R3G total counts
  • RUNX1/RUNX1T1 (ETO/AML1) t(8;21) – 3R2G total counts
  • RUNX1/RUNX1T1 (ETO/AML1) t(8;21) – Nuclei Analyzed
  • RUNX1/RUNX1T1 (ETO/AML1) t(8;21) result
  • RUNX1T1/RUNX1 (ETO/AML1) t(8;21), FISH
  • SARS CoV-2 semi-quantitative Ab panel
  • SARS CoV-2 semi-quantitative total Ab, U/mL
  • SARS-CoV-2 semi-quant total Ab panel
  • SARS-CoV-2 semi-quant total Ab, U/mL
  • SF3B1 mutation analysis – mutation(s)
  • SMAD4 mutation analysis – mutation(s)
  • SMAD4 mutation analysis – SMAD4 mutation analysis
  • SMARCA4 mutation analysis – mutation(s) detected
  • SMARCA4 mutation analysis – SMARCA4 mutation analysis
  • SMARCB1 mutation analysis – mutation(s)
  • SMO mutation analysis – mutation(s)
  • SMO mutation analysis – SMO mutation analysis
  • SRC mutation analysis – mutation(s)
  • SRC mutation analysis – SRC mutation analysis
  • STK11 mutation analysis – mutation(s)
  • TERT Gene Promoter mutation analysis by NGS – mutation(s)
  • TERT Gene Promoter mutation analysis by NGS – TERT Gene Promoter mutation analysis
  • TP53 mutation analysis – TP53 Exon 4
  • TP53 mutation analysis – TP53 Exon 5
  • TP53 mutation analysis – TP53 Exon 6
  • TP53 mutation analysis – TP53 Exon 7
  • TP53 mutation analysis – TP53 Exon 8
  • TP53 mutation analysis – TP53 Exon 9
  • TP53 mutation analysis – TP53 mutation
  • TSC1 mutation analysis – mutation(s) detected
  • TSC1 mutation analysis – TSC1 mutation analysis
  • TSC2 mutation analysis – mutation(s) detected
  • TSC2 mutation analysis – TSC2 mutation analysis
  • Tumor mutation burden – Tumor mutation burden result
  • UGT1A1 genotyping – UGT1A1 activity
  • UGT1A1 genotyping – UGT1A1 genotype detected
  • UGT1A1 genotyping – UGT1A1 promoter TA repeat
  • UGT1A1 genotyping – UGT1A1 SNP
  • UGT1A1 genotyping comments
  • UGT1A1 genotyping panel – NeoGenomics
  • UR blood, qual
  • Urinalysis for blood panel
  • VHL mutation analysis – mutation(s)

Medications

Additions

  • ALKS 4230 invest IV
  • Antroquinonol invest Oral
  • APS001F invest IV
  • ASTX660 invest Oral
  • Cosela (Trilaciclib IV)
  • GSK2118436 invest Oral
  • HL-085 invest Oral
  • Hocena (Antroquinonol invest Oral)
  • Hydromorphone (Carpuject) IM
  • Hydromorphone (Carpuject) IV
  • Hydromorphone (Carpuject) Subcutaneous
  • IMP7068 invest Oral
  • JTX-8064 invest IV
  • LAE001 invest Oral
  • LUT014 invest Topical Gel
  • MRX34 invest IV
  • ON 123300 invest Oral
  • PTG-300 invest Subcutaneous
  • PVSRIPO invest Tumoral
  • PX-12 invest IV
  • RO5185426 invest Oral
  • RO5185426 invest Oral (Vemurafenib invest)
  • S-1 invest Oral
  • SEA-TGT invest IV
  • SQL70 invest Intratumoral
  • SQP33 invest IV
  • TAK-981 invest IV
  • Tepotinib Oral (Tepmetko)
  • Tirapazamine invest IV
  • Tomivosertib invest Oral
  • Matuzumab invest IV
  • Matuzumab invest IV (Emd 72000 invest)
  • MEDI2228 invest IV
  • MLN9708 invest IV
  • Trilaciclib IV
  • Umbralisib Oral (Ukoniq)

Updates

  • Chantix (Varenicline Oral): Default Quick Sig Pick is now1 mg orally daily
  • Ibrance (Palbociclib Oral): Default form is now 125 mg
  • Hydrocortisone IV: Quick Sig Pick updated to 16 mg/kg intravenously 2 time per day.
  • LY3023414 invest Oral : Form: 50 mg Tablet is now
Drug Name New Maximum Single Dose Rounding Rule
Aldesleukin, inj 108 million units
Alectinib Oral 1200 mg/day
Bicalutamide Oral 150 mg
Bleomycin IM 50 UNITS
Brigatinib Oral Dose Pack 180 mg
Busulfan IV 325 mg
Busulfan Oral 150 mg 2 mg
Cabozantinib Oral (Cometriq) 140 mg
Carmustine IV 750 mg
Cisplatin Intraperitoneal None
Clofarabine IV 63 mg
Crizotinib Oral 500 mg; 1000 mg/day
Decitabine Subutaneous 50 mg
Doxorubicin Liposomal IV None
Eltrombopag Oral Powder 150 mg
Eltrombopag Oral 150 MG
Flutamide Oral 250 mg; 750 mg/day
Granisetron (PF) IV 1500 mcg 10 mcg
Hydroxyurea Oral 3000 mg 100 mg
Idarubicin IV none
Lutetium Lu 177 Dotatate IV 10 mCi/mL (370 mBq/mL) 7.4 GBq; 200 mCi
Nilotinib Oral 800 mg/day
Olaparib Oral Tablet 600 mg/day
Pexidartinib Oral 800 mg/day
Tbo-Filgrastim Subcutaneous 1500 mcg
Telotristat Oral 250 mg; 750 mg/day
Tretinoin Oral 60 mg; 120 mg/day
Voxelotor Oral 2500 mg
Zoledronic Acid IV (Zometa) 4 mg

Regimens

  • Added Nyvepria, syringe (pegfilgrastim-apgf) into all regimens containing growth factor support
  • Added Riabni, inj (rituximab-arrx) into all Rituximab BIOSIMILAR containing regimens
  • All remaining regimens containing manually created Truxima have been swapped resolving issues related to patient education.
  • Based on discussion and vote of the Collaborative Care Committee in January 2021, medications for Infection Prophylaxis have been added as optional into applicable regimen templates.

Additions

The following regimens are now available for ordering in the Regimen Library.

  • Cabazitaxel + Carboplatin + Prednisone Q21D
  • COVID-19 Vaccines
  • Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 1 of 2)
  • Daratumumab IV + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 2 of 2: Daratumumab IV only)
  • Daratumumab SQ + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 1 of 2)
  • Daratumumab SQ + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (MM) (Part 2 of 2: Daratumumab SQ only)
  • Daratumumab SQ + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 1 of 2)
  • Daratumumab SQ + Cyclophosphamide PO + Bortezomib + Dexamethasone (CyBorD) Q28D (Amyloidosis) (Part 2 of 2: Daratumumab SQ only)
  • Ibrutinib + Rituximab IV BIOSIMILAR Q1,8,15,22 Q4M
  • Nivolumab + Cabozantinib Q14D
  • Nivolumab + Cabozantinib Q28D

Removals

The following regimens are no longer available for ordering in the Regimen Library.

  • Capecitabine D1-14 Q21D
  • Capecitabine D1-14 Q21D (Colon, Rectal, Breast)
  • Capecitabine D1-14 Q21D (Ovarian, Bile Duct, Neuroendocrine)
  • Idelalisib
  • Rituximab IV + CHOP Q21D (6 cycles)
  • Rituximab IV BIOSIMILAR + CHOP Q21D (6 cycles)
  • Rituximab IV fb SQ + CHOP Q21D (6 cycles)

Updates

Regimens for the following diagnoses are updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • All Problems
  • Amyloidosis
  • Arthritis, Rheumatoid
  • Bile Duct Cancer (Parent)
  • Bladder Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Esophageal Cancer (Parent)
  • Fallopian Tube Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • Leukemia, Acute Lymphocytic (ALL)
  • Leukemia, Chronic Lymphocytic (CLL)
  • Leukemia, Chronic Myeloid (CML)
  • Lung Cancer, Non-Small Cell (NSCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Multiple Myeloma (MM)
  • Multiple Sclerosis
  • Neuroendocrine Tumor, Carcinoid (Parent)
  • Ovarian and Primary Peritoneal Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Rectal Cancer
  • Renal Cell Carcinoma (RCC)
  • Renal Pelvis and Ureter Cancer
  • Urethral Cancer
  • Uterine Cancer (Parent)
  • Waldenstrom’s Macroglobulinemia

Renames

Previous Name New Name
Capecitabine D1-14 Q21D (Ovarian, Bile Duct, Neuroendocrine) Capecitabine (1000 mg/m2) D1-14 Q21D
Capecitabine D1-14 Q21D (Colon, Rectal, Breast) Capecitabine (1250 mg/m2) D1-14 Q21D
Idelalisib Idelalisib Q30D
Idelalisib + Rituximab IV f/b SQ Q28D Idelalisib + Rituximab IV fb SQ Q28D
Rituximab IV + CHOP Q21D (6 cycles) Rituximab IV + CHOP Q21D
Rituximab IV BIOSIMILAR + CHOP Q21D (6 cycles) Rituximab IV BIOSIMILAR + CHOP Q21D
Rituximab IV fb SQ + CHOP Q21D (6 cycles) Rituximab IV fb SQ + CHOP Q21D

Research

Regimen Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

  • Added Nyvepria, syringe (pegfilgrastim-apgf) into all regimens containing growth factor support
  • Added Riabni, inj (rituximab-arrx) into all regimens where Rituximab BIOSIMILAR products are approved per protocol

The USOR Clinical Trials listed in the table below are updated:

Updated Reference Information Updated Drug Service Order Information Updated Regimen Instructions Other Changes
USOR 17160 X X X
USOR 17164 X X
USOR 18020 X X X The following regimens are now available for ordering:

  • USOR 18020 Part 1B BMS-986253 (D1) + Nivolumab (D1) Q21D
  • USOR 18020 Part 1C Nivolumab (D1,22) + Ipilimumab (D1,22) + BMS-986253 (D1,15,29) Q42D (Cycles 1-2)
  • USOR 18020 Part 1C Nivolumab (D1) + BMS-986253 (D1,15) Q28D (Cycles 3+)
  • USOR 18020 Part 2 Nivolumab (D1) + Ipilimumab (D1) + BMS- 986253 or Placebo (D1) Q21D
  • USOR 18020 Part 2 Nivolumab (D1,22) + Ipilimumab (D1,22) + BMS-986253 or Placebo (D1,15,29) Q42D (Cycles 1-2)
  • USOR 18020 Part 2 Nivolumab (D1) + BMS-986253 or Placebo (D1,15) Q28D (Cycles 3+)
  • The following regimens are no longer available for ordering:
  • USOR 18020 Part 2 Dose Expansion BMS-986253 (D1) + Nivolumab (D1) Q28D
  • USOR 18020 Part 2 Dose Expansion BMS-986253 (D1,15) + Nivolumab (D1) Q28D
USOR 17213 X X X The following regimens are now available for ordering:

  • USOR 17213 Arm B-1 (Reduced Maintenance) Pembrolizumab + BCG
  • USOR 17213 Arm B-2 (Full Maintenance) Pembrolizumab + BCG
  • USOR 17213 Arm B-3 BCG Monotherapy
USOR 19036 X X
USOR 19092 X X
USOR 19151 X
USOR 19187 X X X
USOR 20175 X X
USOR 20216 X

Billing CPT and HCPCS Code Updates

Medication HCPSC Code
Brexucabtagene Autoleucel IV (Tecartus) J3590 per 68 mL
COVID-19 Vac,Ad26(Janssen) (PF) IM (Unapproved) 91303 per 0.5 mL
Doxorubicin IV J9000 per 10 mg
Lisocabtagene Maraleucel IV (Breyanzi) J3590 per 5 mL
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 600 mg-600 mg-20,000 unit/10 mL J9316 per 5 mg
Pertuzumab-Trastuzumab-Hy-zzxf Subcutaneous 1200 mg-600 mg-30,000 unit/15 mL J9316 per 6.67 mg
Remot img sub by pt, non e/m G2250
Brief chkin, 5-10, non e/m G2251
Brief chkin by md/qhp, 11-20 G2252
Infect agen detec ampli probe U0005